[go: up one dir, main page]

MA26933A1 - Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1. - Google Patents

Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.

Info

Publication number
MA26933A1
MA26933A1 MA27006A MA27006A MA26933A1 MA 26933 A1 MA26933 A1 MA 26933A1 MA 27006 A MA27006 A MA 27006A MA 27006 A MA27006 A MA 27006A MA 26933 A1 MA26933 A1 MA 26933A1
Authority
MA
Morocco
Prior art keywords
phenyl
receptor antagonists
pyridine derivatives
neurokinin receptor
neurokinin
Prior art date
Application number
MA27006A
Other languages
English (en)
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26933A1 publication Critical patent/MA26933A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA27006A 2000-07-24 2003-01-22 Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1. MA26933A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24

Publications (1)

Publication Number Publication Date
MA26933A1 true MA26933A1 (fr) 2004-12-20

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27006A MA26933A1 (fr) 2000-07-24 2003-01-22 Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.

Country Status (37)

Country Link
US (2) US6576762B2 (fr)
EP (1) EP1305319B1 (fr)
JP (1) JP4118673B2 (fr)
KR (1) KR100527214B1 (fr)
CN (1) CN1192032C (fr)
AR (1) AR029875A1 (fr)
AT (1) ATE322496T1 (fr)
AU (2) AU8200501A (fr)
BR (1) BR0112695A (fr)
CA (1) CA2416874C (fr)
CY (1) CY1106113T1 (fr)
CZ (1) CZ2003528A3 (fr)
DE (1) DE60118569T2 (fr)
DK (1) DK1305319T3 (fr)
EC (1) ECSP034446A (fr)
ES (1) ES2260265T3 (fr)
GT (1) GT200100148A (fr)
HR (1) HRP20030031A2 (fr)
HU (1) HU229231B1 (fr)
IL (2) IL153837A0 (fr)
JO (1) JO2321B1 (fr)
MA (1) MA26933A1 (fr)
MX (1) MXPA03000367A (fr)
MY (1) MY129224A (fr)
NO (1) NO20030353D0 (fr)
NZ (1) NZ523452A (fr)
PA (1) PA8522801A1 (fr)
PE (1) PE20020258A1 (fr)
PL (1) PL366173A1 (fr)
PT (1) PT1305319E (fr)
RU (1) RU2276139C2 (fr)
SI (1) SI1305319T1 (fr)
TW (1) TWI287003B (fr)
UY (1) UY26851A1 (fr)
WO (1) WO2002008232A1 (fr)
YU (1) YU2803A (fr)
ZA (1) ZA200300219B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
DE60321907D1 (de) 2002-04-26 2008-08-14 Lilly Co Eli Tachykininrezeptorantagonisten
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
WO2004032875A2 (fr) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Preparation de derives d'heteroaryl-diamine a trois atomes d'azote utiles comme agents pharmaceutiques et procedes de fabrication desdits agents
WO2005000821A1 (fr) * 2003-06-12 2005-01-06 Eli Lilly And Company Antagonistes du recepteur tachykinine
HRP20070471T3 (hr) * 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
EP2029559B1 (fr) 2006-05-31 2009-08-05 F. Hoffmann-Roche AG Dérivés d'aryl-4-éthynyl-isoxazole
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016149324A1 (fr) 2015-03-16 2016-09-22 Vanderbilt University Modulateurs allostériques négatifs du récepteur métabotropique du glutamate de type 2
WO2017112792A1 (fr) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Modulateurs tripartites de récepteurs couplés aux protéines g des endosomes
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE364606T1 (de) 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
BR9908895A (pt) 1998-03-19 2000-12-05 Takeda Chemical Industries Ltd Composição farmacêutica, composto, pró-medicamento, composições para antagonizar um receptor, uso de um composto, e, processos para produzir um composto, para antagonizar um receptor, para evitar ou tratar distúrbios de micção em mamìferos e distúrbios de asma, artrite reumatóide, osteoartrite, dor, tosse, sìndrome do intestino irritável ou vÈmitos em mamìferos
ES2226622T3 (es) 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
BR0008489A (pt) * 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
JP4068305B2 (ja) * 1999-02-24 2008-03-26 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
HU230316B1 (hu) * 2000-07-14 2016-01-28 F. Hoffmann-La Roche Ag N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
MY129224A (en) 2007-03-30
EP1305319B1 (fr) 2006-04-05
TWI287003B (en) 2007-09-21
BR0112695A (pt) 2003-04-22
KR20030015898A (ko) 2003-02-25
ATE322496T1 (de) 2006-04-15
CY1106113T1 (el) 2011-06-08
US20020038030A1 (en) 2002-03-28
CA2416874A1 (fr) 2002-01-31
ES2260265T3 (es) 2006-11-01
MXPA03000367A (es) 2003-05-27
SI1305319T1 (sl) 2006-08-31
NO20030353L (no) 2003-01-23
HU229231B1 (en) 2013-09-30
JO2321B1 (en) 2005-09-12
WO2002008232A1 (fr) 2002-01-31
HRP20030031A2 (en) 2004-02-29
US6624176B2 (en) 2003-09-23
ECSP034446A (es) 2003-03-10
CN1444589A (zh) 2003-09-24
IL153837A0 (en) 2003-07-31
HK1058360A1 (en) 2004-05-14
AU8200501A (en) 2002-02-05
CZ2003528A3 (cs) 2003-09-17
DK1305319T3 (da) 2006-08-14
IL153837A (en) 2008-06-05
JP4118673B2 (ja) 2008-07-16
DE60118569T2 (de) 2007-02-15
PT1305319E (pt) 2006-08-31
CN1192032C (zh) 2005-03-09
JP2004504400A (ja) 2004-02-12
US6576762B2 (en) 2003-06-10
NZ523452A (en) 2004-07-30
PL366173A1 (en) 2005-01-24
RU2276139C2 (ru) 2006-05-10
AR029875A1 (es) 2003-07-16
YU2803A (sh) 2006-01-16
PE20020258A1 (es) 2002-04-02
US20030130508A1 (en) 2003-07-10
DE60118569D1 (de) 2006-05-18
GT200100148A (es) 2002-05-16
PA8522801A1 (es) 2002-09-30
HUP0301272A2 (hu) 2003-08-28
EP1305319A1 (fr) 2003-05-02
UY26851A1 (es) 2002-01-31
CA2416874C (fr) 2011-01-18
AU2001282005B2 (en) 2006-10-19
ZA200300219B (en) 2004-04-08
KR100527214B1 (ko) 2005-11-08
NO20030353D0 (no) 2003-01-23

Similar Documents

Publication Publication Date Title
MA26933A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.
MA27680A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1
MA26971A1 (fr) Derives de phenylethenyle ou de phenylethinyle en tant qu'antagonistes de recepteur de glutamate
EP1268449A4 (fr) Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
DE60134762D1 (de) Metabotropische glutamatrezeptor-antagonisten
FR17C0008I2 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
EP1320366A4 (fr) Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
MA25366A1 (fr) Sulfonamides d'hydroxy-diphenyl cree en tant qu'antagonistes du recepteur il-8.
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
MA27679A1 (fr) Derives d'acides carboxyliques en tant qu'antagonistes ip
MA27124A1 (fr) 4-(heterocyclysulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl ou pyridylpyrimidines utilisees en tant qu'antagonistes des recepteurs d'endotheline.
DK1440059T3 (da) 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
MA26958A1 (fr) Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
MA27046A1 (fr) Nouveaux derives d'oxazolidinones en tant qu'agents antibacteriens.
NO20013709D0 (no) Nye N-triazolylmetyl-piperazinderivater som neurokininreseptorantagonister
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
DE60141896D1 (de) N,n'-diarylguanidine als il-8-rezeptor-antagonisten
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
EP1169042A4 (fr) Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine
ATE310732T1 (de) 7-phenyl-1,4-diazepanderivate als neurokininrezeptorantagonisten
SE0003996D0 (sv) Receptorantagonister
DK1077942T3 (da) Carboxysubstituerede carboxamidderivater som tachykininreceptorantagonister